Background. Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/ TAF) 800/150/200/10 mg is a once-daily, single-tablet regimen approved in Europe and under regulatory review in the United States for the treatment of HIV-1 infection. In the pivotal AMBER trial in antiretroviral treatment (ART)-naïve, HIV-1-infected adults, D/C/F/TAF achieved a high virologic response rate at Week 48 that was noninferior to control (D/C+F/tenofovir disoproxil fumarate); favorable renal/bone outcomes were seen with D/C/F/TAF vs. control. These results were consistent across age, gender, and race subgroups. Here we report Week 48 results in subgroups based on viral load (VL), CD4 + count, and WHO clinical staging of HIV/AIDS at baseline. Methods. The phase 3, randomized (1:1), blinded, noninferiority AMBER trial enrolled ART-naïve, HIV-1-infected adults. The primary endpoint was the proportion of patients with virologic response (VL <50 copies/mL; FDA snapshot) at Week 48. Adverse events (AEs) and laboratory parameters were monitored throughout the study. Results were evaluated in subgroups based on VL (≤ vs. >100,000 copies/mL), CD4 + count (< vs. ≥350 cells/µL), and WHO clinical stage (1 vs. 2 vs. 3 vs. 4) at baseline. Results. Of the 725 patients randomized and treated, the majority had VL ≤100,000 copies/mL (82% of patients), CD4
+ count ≥350 cells/µL (72%), and WHO clinical stage 1 (84%) at baseline. Overall virologic response rates were 91.4% with D/C/F/TAF and 88.4% with control; results were similar across baseline VL, CD4 
